drugset / Trial / NCT03711825

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults

NCT03711825

Phase 0 Completed 8 enrolled Lyndra Inc.
NaSingle-groupOpen-labelTreatment

Summary

To assess how long memantine hydrochloride (HCl) (50 mg) extended release capsules stay in the stomach as determined by imaging assessment (MRI or abdominal ultrasound). To evaluate the safety of a memantine HCl extended release capsule formulation

Timeline

Start
2018-09-10
Primary completion
2018-10-01
Completion
2018-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 50 mg